Literature DB >> 30266507

Hospitalization for Respiratory Syncytial Virus in Children with Down Syndrome Less than 2 Years of Age: A Systematic Review and Meta-Analysis.

Souvik Mitra1, Mohamed El Azrak2, Helen McCord3, Bosco A Paes4.   

Abstract

OBJECTIVES: To compare the respiratory syncytial virus (RSV)-related hospitalization rate, hospital length of stay (LOS), and need for assisted ventilation in children aged <2 years with Down syndrome and those without Down syndrome. STUDY
DESIGN: MEDLINE, Embase, and CINAHL databases were searched from inception up to December 2017. Studies that provided data on RSV-related hospitalization in children aged <2 years with Down syndrome and those without Down syndrome were included. Data were independently extracted in pairs by 2 reviewers and synthesized with random-effects meta-analysis.
RESULTS: In 10 studies including a total of 1 748 209 children, 12.6% of the children with Down syndrome (491 of 3882) were hospitalized with RSV infection. The presence of Down syndrome was associated with a significantly higher risk of RSV-related hospitalization (relative risk [RR], 6.06; 95% CI, 4.93-7.45; I2 = 65%; Grading of Recommendations, Assessment, Development and Evaluation [GRADE], moderate). RSV-related LOS (mean difference, 2.11 days; 95% CI, 1.47-2.75 days; I2 = 0%; GRADE, low), and the need for assisted ventilation (RR, 5.82; 95% CI, 1.81-18.69; I2 = 84%; GRADE, low). Children with Down syndrome without congenital heart disease (RR, 6.31; 95% CI, 4.83-8.23; GRADE, moderate) also had a significantly higher risk of RSV-related hospitalization. The risk of RSV-related hospitalization remained significant in the subgroup of children aged <1 year (RR, 6.25; 95% CI, 4.71-8.28; GRADE, high).
CONCLUSION: RSV-related hospitalization, hospital LOS, and the need for assisted ventilation are significantly higher in children with Down syndrome aged <2 years compared with those without Down syndrome. The results should prompt reconsideration of the need for routine RSV prophylaxis in children with Down syndrome up to 2 years of age.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  GRADE; RSV immunoprophylaxis; congenital heart disease; random-effects model

Mesh:

Year:  2018        PMID: 30266507     DOI: 10.1016/j.jpeds.2018.08.006

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  6 in total

1.  Clinical characteristics and comorbidities of COVID-19 in unvaccinated patients with Down syndrome: first year report in Brazil.

Authors:  Matheus Negri Boschiero; Camila Vantini Capasso Palamim; Fernando Augusto Lima Marson; Manoela Marques Ortega
Journal:  Hum Genet       Date:  2022-06-28       Impact factor: 5.881

2.  Universal palivizumab prophylaxis for children with Down syndrome in Japan: analysis with interrupted time-series.

Authors:  Masato Takeuchi; Koji Kawakami
Journal:  Hum Vaccin Immunother       Date:  2020-09-22       Impact factor: 3.452

3.  The impact of obstructive sleep apnea on bronchiolitis severity in children with Down syndrome.

Authors:  Po-Yang Tsou; Christopher M Cielo; Melissa S Xanthopoulos; Yu-Hsun Wang; Pei-Lun Kuo; Ignacio E Tapia
Journal:  Sleep Med       Date:  2021-04-16       Impact factor: 4.842

4.  Reappraisal of the Subtropical Guidelines on Palivizumab Prophylaxis in Congenital Heart Disease.

Authors:  Shuenn-Nan Chiu; Ching-Chia Wang; Ming-Tai Lin; Chun-An Chen; Chun-Wei Lu; Yu-Chuan Hua; Jing-Ming Wu; Mei-Hwan Wu; Jou-Kou Wang
Journal:  Front Pediatr       Date:  2022-01-05       Impact factor: 3.418

Review 5.  Immune Dysregulation and the Increased Risk of Complications and Mortality Following Respiratory Tract Infections in Adults With Down Syndrome.

Authors:  Tomer Illouz; Arya Biragyn; Maria Florencia Iulita; Lisi Flores-Aguilar; Mara Dierssen; Ilario De Toma; Stylianos E Antonarakis; Eugene Yu; Yann Herault; Marie-Claude Potier; Alexandra Botté; Randall Roper; Benjamin Sredni; Jacqueline London; William Mobley; Andre Strydom; Eitan Okun
Journal:  Front Immunol       Date:  2021-06-25       Impact factor: 7.561

6.  Respiratory Syncytial Virus-related Death in Children With Down Syndrome: The RSV GOLD Study.

Authors:  Yvette N Löwensteyn; Emily W E M Phijffer; Juliette V L Simons; Nienke M Scheltema; Natalie I Mazur; Harish Nair; Louis J Bont
Journal:  Pediatr Infect Dis J       Date:  2020-08       Impact factor: 3.806

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.